In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory ...

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

A novel combination for relapsed/refractory multiple myeloma produced responses in about 80% of a heavily treated population, ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...

Delayed diagnosis causes a significant disadvantage for Hungarian patients adding cost and complexity to the already stretched healthcare system.

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...

Researchers sought to determine whether patients who are functional high-risk had a worse prognosis even without having traditional high-risk features.

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.